Pre-earnings options volume in Corvus Pharmaceuticals (CRVS) is normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 7.9%, or $1.28, after results are released. Median move over the past eight quarters is 9.8%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market
- Corvus Advances Soquelitinib Into Phase 2 Eczema Trial: What Investors Should Watch
- Corvus Pharmaceuticals options imply 5.5% move in share price post-earnings
- CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- 3 ‘Strong Buy’ Biotech Stocks to Buy Now, 1/29/2026, According to Top Analysts